Thrombopoietin mimetics
AssigneeSmithKline Beecham Corporation and Glaxo Group Limited
InventorsKevin Duffy, Connie Erickson-Miller, Julian Jenkins, Juan Luengo, Sophie Visonneau
Life of this patent
Estimating the term…
Abstract
Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
Claims23
A compound selected from the group consisting essentially of:
- 3-{N′-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2-hydroxy-3′-(tetrazol-5-yl)biphenyl, and a pharmaceutically acceptable salt, a hydrate, a solvate, and an ester, thereof.
A compound selected from the group consisting essentially of:
- 3′-{N′-[1-(4-tert-butylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2′-hydroxybiphenyl-3-carboxylic acid, and a pharmaceutically acceptable salt, a hydrate, a solvate, and an ester, thereof.
A compound selected from the group consisting essentially of:
- 3-Aza-3′-{N′-[1-(4-tert-butylpbenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2′-hydroxybiphenyl-5-carboxylic acid, and a pharmaceutically acceptable salt, a hydrate, a solvate, and an ester, thereof.
Dependencies are inferred from the claim text.